From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
nab-Paclitaxel Dose Cohorta, n (%)
CMR
PMR
SMD
PMD
100 mg/m2 (n = 13)
3 (23)
7 (54)
0
125 mg/m2 (n = 38)
13 (34)
25 (66)